Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by NovImmune SA
Sponsor:
Collaborator:
Seventh Framework Programme
Information provided by (Responsible Party):
NovImmune SA
ClinicalTrials.gov Identifier:
NCT01818492
First received: March 21, 2013
Last updated: June 23, 2016
Last verified: June 2016
  Purpose
The purpose of this study is to assess the safety, tolerability and efficacy of a new drug aimed at controlling disease activity in patients diagnosed with primary haemophagocytic lymphohistiocytosis. The new drug can be administered as the first-line therapy, to patients not previously treated with the current standard of care, or can be given to patients who have either failed or were unable to tolerate the current standard of care. Administration will be on top of a glucocorticosteroid, which is usually part of the current recommended treatment.

Condition Intervention Phase
Primary Haemophagocytic Lymphohistiocytosis
Biological: NI-0501
Phase 2
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis

Resource links provided by NLM:


Further study details as provided by NovImmune SA:

Primary Outcome Measures:
  • Overall response rate [ Time Frame: end of treatment ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Time to response [ Time Frame: any time during the study ] [ Designated as safety issue: No ]
  • Durability of response [ Time Frame: any time during the study ] [ Designated as safety issue: No ]
  • Survival [ Time Frame: end of the study and beyond ] [ Designated as safety issue: No ]
  • Glucocorticoid tapering [ Time Frame: any time during the study ] [ Designated as safety issue: No ]
  • Safety and tolerability of NI-0501 in haemophagocytic lymphohistiocytosis [ Time Frame: up to end of the study ] [ Designated as safety issue: No ]
    • Vital signs
    • Physical examination
    • Recording of adverse events
    • Routine laboratory assessments


Estimated Enrollment: 32
Study Start Date: January 2013
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NI-0501 Biological: NI-0501

  Eligibility

Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Gender: male and female
  • Age: up to and including 18 years at diagnosis of Haemophagocytic Lymphohistiocytosis
  • Primary HLH patients
  • Patient (if ≥ 18 years old), or patient's legal representative(s) must have signed informed consent

Exclusion Criteria:

  • Diagnosis of secondary Haemophagocytic Lymphohistiocytosis consequent to a proven rheumatic or neoplastic disease.
  • Body weight < 3 kg.
  • Patients treated with biologics within a specific timeframe
  • Active Mycobacteria, Histoplasma Capsulatum, Shigella, Salmonella, Campylobacter and Leishmania infections.
  • Presence of malignancy.
  • Concomitant disease or malformation severely affecting the cardiovascular, pulmonary, liver or renal function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01818492

Contacts
Contact: Cristina de Min, MD +41-22-593- ext 5116 cdemin@novimmune.com

Locations
United States, Colorado
Children's Hospital Colorado Recruiting
Aurora, Colorado, United States, 80045-7106
Contact: Timothy Garrington, MD    720-777-6740    timothygarrington@childrenscolorado.org   
Principal Investigator: Timothy Garrington, MD         
United States, Delaware
Alfred I. duPont Hospital for Children - Nemours Center for Cancer and Blood Disorders - Division of Pediatric Hematology Oncology Recruiting
Wilmington, Delaware, United States, 19803
Contact: Jonathan Powell, MD    302-651-5505    Jonathan.Powell@nemours.org   
Principal Investigator: Jonathan Powell, MD         
United States, Massachusetts
Dana-Farber Cancer Institute (DFCI) Recruiting
Boston, Massachusetts, United States, 02115
Contact: Barbara A Degar, MD    617-632-5186    Barbara_Degar@dfci.harvard.edu   
Principal Investigator: Barbara A Degar, MD         
United States, North Carolina
University of North Carolina at Chapel Hill Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Philip A Roehrs, MD    919-962-8733    roehrs@email.unc.edu   
Principal Investigator: Philip A Roehrs, MD         
United States, Ohio
Cincinnati Children's Hospital - Division of Immunobiology - Department of Pediatrics Recruiting
Cincinnati, Ohio, United States, 45229-3039
Contact: Michael Jordan, MD    513-636-7287    Michael.Jordan@cchmc.org   
Principal Investigator: Michael Jordan, MD         
United States, Texas
Texas Children's Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Carl Allen, MD, PhD    832-824-4312    ceallen@txch.org   
Principal Investigator: Carl Allen, MD, PhD         
United States, Utah
Primary Children's Hospital Recruiting
Salt Lake City, Utah, United States, 84113
Contact: Mark N Fluchel, MD    801-662-4710    Mark.Fluchel@imail2.org   
Principal Investigator: Mark N Fluchel, MD         
Austria
St. Anna Children's Hospital Recruiting
Vienna, Austria, A-1090
Contact: Wolfgang Holter, MD    0043 1 40 170 1250    wolfgang.holter@stanna.at   
Principal Investigator: Wolfgang Holter, MD         
Germany
University Children's Hospital Recruiting
Münster, Germany, 48149
Contact: Claudia Rössig, Prof. Dr. Med.    0049 2518347742    rossig@ukmuenster.de   
Principal Investigator: Claudia Rössig, Prof. Dr. Med.         
Italy
Azienda Ospedaliero Universitaria Meyer Recruiting
Florence, Italy, 50139
Contact: Elena Sieni, MD    +39 055-5662 ext 524    e.sieni@meyer.it   
Principal Investigator: Elena Sieni, MD         
Istituto Giannina Gaslini Recruiting
Genoa, Italy, 16147
Contact: Concetta Micalizzi, MD    0039_010_5636 ext 715    concettamicalizzi@ospedale-gaslini.ge.it   
Principal Investigator: Concetta Micalizzi, MD         
Azienda Ospedaliera San Gerardo Recruiting
Monza, Italy, 20900
Contact: Carmelo Rizzari, MD    0039_039_233 ext 3513    c.rizzari@hsgerardo.org   
Principal Investigator: Carmelo Rizzari, MD         
Azienda Ospedaliera Padova - Clinica di Oncoematologia Pediatrica Recruiting
Padua, Italy, 35128
Contact: MariaCaterina Putti, MD    0039 049 8213535    mariacaterina.putti@unipd.it   
Principal Investigator: Mariacaterina Putti, MD         
Ospedale Pediatrico Bambino Gesu' Recruiting
Roma, Italy, 00165
Contact: Franco Locatelli, MD    0039 06 68592678    franco.locatelli@opbg.net   
Principal Investigator: Franco Locatelli, MD         
Policlinico G.B. Rossi - U.O.C. Oncoematologia Pediatrica Recruiting
Verona, Italy, 37134
Contact: Simone Cesaro, MD    0039 045 8124931    simone.cesaro@ospedaleuniverona.it   
Principal Investigator: Simone Cesaro, MD         
Spain
Hospital Universitario Vall d'Hebron Recruiting
Barcelona, Spain, 119-129
Contact: Jose Sanchez de Toledo, MD    0034 934893093    jossanchez@vhebron.net   
Principal Investigator: Jose Sanchez de Toledo, MD         
Hospital Sant Joan de Déu Recruiting
Esplugues de Llobregat (Barcelona), Spain, 08950
Contact: Laia Alsina Manrique de Lara, MD    0034 932804000 ext 3330    lalsina@hsjdbcn.org   
Principal Investigator: Laia Alsina, MD         
Hospital Universitario Niño Jesús Recruiting
Madrid, Spain, 28009
Contact: Julian Sevilla, MD    0034 915035938    julian.sevilla@salud.madrid.org   
Principal Investigator: Julian Sevilla, MD         
Sweden
Karolinska University Hospital Recruiting
Stockholm, Sweden, 17176
Contact: Jan-Inge Henter, MD    0046851772484      
Principal Investigator: Jan-Inge Henter         
Turkey
Hacettepe University - Paediatric Hematology Recruiting
Ankara, Turkey, 06100
Contact: Sule Unal, MD    0090 532 526 37 49    suleunal@hacettepe.edu.tr   
Principal Investigator: Sule Unal, MD         
Sponsors and Collaborators
NovImmune SA
Seventh Framework Programme
  More Information

Responsible Party: NovImmune SA
ClinicalTrials.gov Identifier: NCT01818492     History of Changes
Other Study ID Numbers: NI-0501-04  2012-003632-23 
Study First Received: March 21, 2013
Last Updated: June 23, 2016
Health Authority: Italy: The Italian Medicines Agency
Austria: Federal Office for Safety in Health Care
Germany: Paul Ehrlich Institute, PEI
Spain: Agencia Espanola de Medicamentos y Productos Sanitarios AEMPS
United States: Food and Drug Administration
Sweden: Medical Products Agency
Turkey: Drug and Medical Device Institution

Additional relevant MeSH terms:
Lymphohistiocytosis, Hemophagocytic
Histiocytosis, Non-Langerhans-Cell
Histiocytosis
Lymphatic Diseases

ClinicalTrials.gov processed this record on September 27, 2016